NCT06989957View on ClinicalTrials.gov

Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 17, 2025

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2029

Conditions
Posttraumatic Stress Disorder
Interventions
DRUG

Psilocybin

Experimental Psilocybin (exact dosages not disclosed)

DRUG

Psilocybin

Comparator Psilocybin (exact dosages not disclosed)

DRUG

MDMA

Experimental MDMA (exact dosages not disclosed)

DRUG

MDMA

Comparator MDMA (exact dosages not disclosed)

Trial Locations (1)

21224

RECRUITING

Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore

All Listed Sponsors
collaborator

Gracias Family Foundation

UNKNOWN

lead

Johns Hopkins University

OTHER